Occudo Quantitative Strategies’s Anika Therapeutics ANIK Stock Holding History

Occudo Quantitative Strategies’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$197K	Sell	13,460 -2,227	-14%	-$33K	0.01%	691
2026 Q1	$195K	Sell	15,687 -9,823	-39%	-$114K	0.01%	675
2025 Q4	$245K	Buy	25,510 +15,407	+152%	+$148K	0.02%	544
2025 Q3	$95K	Buy	+10,103	New	+$96.5K	0.01%	625
2024 Q1	–	Sell	-10,924	Closed	-$248K	–	723
2023 Q4	$248K	Buy	+10,924	New	+$226K	0.03%	589
2023 Q3	–	Sell	-11,600	Closed	-$301K	–	957
2023 Q2	$301K	Buy	+11,600	New	+$310K	0.03%	736

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Occudo Quantitative Strategies's ANIK Position: Q2 2026 in Review

Occudo Quantitative Strategies reduced its Anika Therapeutics (ANIK) stake by 14% in Q2 2026, selling an estimated $33K and leaving 13,460 shares worth $197K. The position accounts for 0.01% of the portfolio, ranked #691.

Occudo Quantitative Strategies first reported a position in ANIK in Q2 2023 and has held it in 6 quarters since. The position peaked at $301K in Q2 2023. 134 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

Occudo Quantitative Strategies held 13,460 shares of Anika Therapeutics worth $197K as of Q2 2026.
Occudo Quantitative Strategies sold 2,227 Anika Therapeutics shares in Q2 2026, an estimated $33K.
Anika Therapeutics made up 0.01% of Occudo Quantitative Strategies's portfolio in Q2 2026, its #691 holding.
Occudo Quantitative Strategies first reported a position in Anika Therapeutics in Q2 2023 and has held it in 6 quarters since.
Occudo Quantitative Strategies's Anika Therapeutics position peaked at $301K in Q2 2023.
134 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on Occudo Quantitative Strategies's 13F filing for Q2 2026, filed 13 Aug 2026.